用于治疗急性髓系白血病的双特异性抗体
Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.
作者信息
Guy Daniel G, Uy Geoffrey L
机构信息
Division of Oncology, Washington University School of Medicine, 660 S. Euclid Ave, CB 8007, St. Louis, MO, 63110, USA.
出版信息
Curr Hematol Malig Rep. 2018 Dec;13(6):417-425. doi: 10.1007/s11899-018-0472-8.
Abstract
PURPOSE OF REVIEW
Bispecific antibodies combine antigen recognition sites from two or more antibodies into a single construct allowing simultaneous binding to multiple targets. Bispecific antibodies exist which can redirect immune effector cells against acute myeloid leukemia (AML) targets. This review will highlight the progress to date and the challenges in developing bispecific antibodies for the treatment of AML.
RECENT FINDINGS
Currently, a number of bispecific antibody formats including bispecific T cell engagers, dual affinity retargeting proteins, and tandem diabodies are in clinical development for AML. These antibodies target antigens present on AML blasts, including CD33, and the low affinity IL3 receptor, CD123. T cell redirecting bispecific antibodies in early phase clinical trials for AML include AG330, flotetuzumab, JNJ-63709178, and AMV564. Bispecific antibodies represent a promising immunotherapeutic approach for the treatment of cancer. The results of ongoing studies in AML will elucidate the potential for these agents in AML.
摘要
综述目的
双特异性抗体将来自两种或更多种抗体的抗原识别位点组合在一个构建体中，使其能够同时结合多个靶点。存在能够使免疫效应细胞重新靶向急性髓系白血病（AML）靶点的双特异性抗体。本综述将重点介绍目前在开发用于治疗AML的双特异性抗体方面取得的进展和面临的挑战。
最新发现
目前，包括双特异性T细胞衔接器、双亲和力重定向蛋白和串联双抗体在内的多种双特异性抗体形式正在针对AML进行临床开发。这些抗体靶向AML原始细胞上存在的抗原，包括CD33和低亲和力白细胞介素3受体CD123。用于AML早期临床试验的T细胞重定向双特异性抗体包括AG330、flotetuzumab、JNJ-63709178和AMV564。双特异性抗体是一种有前景的癌症免疫治疗方法。正在进行的AML研究结果将阐明这些药物在AML中的潜力。
相似文献
1
Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.用于治疗急性髓系白血病的双特异性抗体
Curr Hematol Malig Rep. 2018 Dec;13(6):417-425. doi: 10.1007/s11899-018-0472-8.
2
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.急性髓系白血病中抗体类药物治疗的临床评估进展
Curr Hematol Malig Rep. 2021 Feb;16(1):89-96. doi: 10.1007/s11899-021-00612-w. Epub 2021 Feb 25.
3
Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.使用T细胞导向双亲和重定向平台靶向急性髓系白血病中的CD123
Blood. 2016 Jan 7;127(1):122-31. doi: 10.1182/blood-2014-05-575704. Epub 2015 Nov 3.
4
Emerging Immunotherapy for Acute Myeloid Leukemia.急性髓系白血病的新兴免疫疗法。
Int J Mol Sci. 2021 Feb 16;22(4):1944. doi: 10.3390/ijms22041944.
5
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors.急性髓系白血病的免疫治疗：聚焦于单克隆抗体和免疫检查点抑制剂。
Curr Opin Hematol. 2018 Mar;25(2):136-145. doi: 10.1097/MOH.0000000000000401.
6
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.用于治疗急性髓系白血病的 CD33/CD3 四价双特异性串联双抗体（TandAbs）的表征。
Clin Cancer Res. 2016 Dec 1;22(23):5829-5838. doi: 10.1158/1078-0432.CCR-16-0350. Epub 2016 May 17.
7
Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager.使用 AMV564（一种双价双特异性 CD33 x CD3 T 细胞衔接器）控制急性髓系白血病并在体内产生免疫记忆。
PLoS One. 2024 May 2;19(5):e0300174. doi: 10.1371/journal.pone.0300174. eCollection 2024.
8
CD123 bi-specific antibodies in development in AML: What do we know so far?在 AML 中开发的 CD123 双特异性抗体：目前我们了解多少？
Best Pract Res Clin Haematol. 2020 Dec;33(4):101219. doi: 10.1016/j.beha.2020.101219. Epub 2020 Nov 6.
9
Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.用于将T细胞重新靶向急性髓系白血病母细胞的双特异性抗体释放间充质基质细胞机制。
Blood Cancer J. 2015 Sep 18;5(9):e348. doi: 10.1038/bcj.2015.73.
10
Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.双特异性抗体选择性招募 γδ T 细胞治疗急性髓系白血病。
Leukemia. 2021 Aug;35(8):2274-2284. doi: 10.1038/s41375-021-01122-7. Epub 2021 Feb 1.
引用本文的文献
1
Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment.免疫细胞衔接器：推动癌症治疗的精准免疫疗法
Antibodies (Basel). 2025 Feb 11;14(1):16. doi: 10.3390/antib14010016.
2
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.急性髓系白血病：2025年诊断、风险分层及管理的最新进展
Am J Hematol. 2025 May;100(5):860-891. doi: 10.1002/ajh.27625. Epub 2025 Feb 12.
3
Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies.逻辑门控和实体瘤免疫治疗的语境控制：对比多特异性 T 细胞衔接器和 CAR-T 细胞疗法。
Front Immunol. 2024 Nov 13;15:1490911. doi: 10.3389/fimmu.2024.1490911. eCollection 2024.
4
Bispecific antibody (ABL602 2 + 1) induced bistable acute myeloid leukemia kinetics.双特异性抗体（ABL602 2+1）诱导双稳态急性髓系白血病动力学。
Sci Rep. 2024 Oct 26;14(1):25557. doi: 10.1038/s41598-024-75971-4.
5
A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia.一种新型双特异性 T 细胞衔接子，使用配体靶向 csGRP78 对抗急性髓系白血病。
Cell Mol Life Sci. 2024 Aug 28;81(1):371. doi: 10.1007/s00018-024-05410-0.
6
IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells.IL1RAP 特异性 T 细胞衔接器耗竭急性髓系白血病干细胞。
J Hematol Oncol. 2024 Aug 14;17(1):67. doi: 10.1186/s13045-024-01586-x.
7
Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager.使用 AMV564（一种双价双特异性 CD33 x CD3 T 细胞衔接器）控制急性髓系白血病并在体内产生免疫记忆。
PLoS One. 2024 May 2;19(5):e0300174. doi: 10.1371/journal.pone.0300174. eCollection 2024.
8
A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ-induced CD38 expression.一种靶向 CD38 的单链 T 细胞衔接子通过 IFN-γ 诱导的 CD38 表达靶向白血病干细胞。
Blood. 2024 Apr 18;143(16):1599-1615. doi: 10.1182/blood.2023021570.
9
Bispecific Antibodies in Hematological Malignancies: A Scoping Review.血液系统恶性肿瘤中的双特异性抗体：一项范围综述
Cancers (Basel). 2023 Sep 14;15(18):4550. doi: 10.3390/cancers15184550.
10
Insights into the New Molecular Updates in Acute Myeloid Leukemia Pathogenesis.急性髓系白血病发病机制中的新分子研究进展。
Genes (Basel). 2023 Jul 10;14(7):1424. doi: 10.3390/genes14071424.
本文引用的文献
1
Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity.双特异性 CD3xCD123 DART 分子在非人灵长类动物中的药代动力学/药效学综合模型：活性评估和免疫原性影响。
Clin Cancer Res. 2018 Jun 1;24(11):2631-2641. doi: 10.1158/1078-0432.CCR-17-2265. Epub 2018 Feb 20.
2
Gemtuzumab ozogamicin for acute myeloid leukemia.吉妥珠单抗奥佐米星治疗急性髓细胞白血病。
Blood. 2017 Nov 30;130(22):2373-2376. doi: 10.1182/blood-2017-09-797712. Epub 2017 Oct 11.
3
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.奥英妥珠单抗治疗复发或难治性急性淋巴细胞白血病成年患者的肝脏不良事件情况：开放标签、随机、3期INO-VATE研究结果
Lancet Haematol. 2017 Aug;4(8):e387-e398. doi: 10.1016/S2352-3026(17)30103-5. Epub 2017 Jul 4.
4
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.CD33剪接多态性决定初治急性髓系白血病中吉妥珠单抗奥唑米星的疗效：儿童肿瘤协作组III期随机试验AAML0531的报告
J Clin Oncol. 2017 Aug 10;35(23):2674-2682. doi: 10.1200/JCO.2016.71.2513. Epub 2017 Jun 23.
5
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.博纳吐单抗对比化疗治疗晚期急性淋巴细胞白血病
N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.
6
Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.双靶点双特异性抗体可实现对普遍存在的检查点受体CD47的选择性阻断。
Mol Ther. 2017 Feb 1;25(2):523-533. doi: 10.1016/j.ymthe.2016.11.006.
7
Despite slow progress, bispecifics generate buzz.尽管进展缓慢，但双特异性抗体仍引起了轰动。
Nat Biotechnol. 2016 Dec 7;34(12):1215-1217. doi: 10.1038/nbt1216-1215.
8
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.用于治疗急性髓系白血病的 CD33/CD3 四价双特异性串联双抗体（TandAbs）的表征。
Clin Cancer Res. 2016 Dec 1;22(23):5829-5838. doi: 10.1158/1078-0432.CCR-16-0350. Epub 2016 May 17.
9
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.白细胞介素15三特异性杀伤细胞衔接器（TriKE）使自然杀伤细胞对CD33+靶点具有特异性，同时还能诱导其持久性、体内扩增及功能增强。
Clin Cancer Res. 2016 Jul 15;22(14):3440-50. doi: 10.1158/1078-0432.CCR-15-2710. Epub 2016 Feb 4.
10
Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.使用T细胞导向双亲和重定向平台靶向急性髓系白血病中的CD123
Blood. 2016 Jan 7;127(1):122-31. doi: 10.1182/blood-2014-05-575704. Epub 2015 Nov 3.
Zotero 插件